HLX22 
GtoPdb Ligand ID: 13443
|
Compound class:
Antibody
Comment: HLX22 is a humanized anti-HER2 (EGFR2; ERBB2) IgG1 monoclonal antibody. It binds within the same HER2 subdomain as trastuzumab, but at a separate, non-overlapping epitope [1]. HLX22 is proposed to offer synergistic antitumour efficacy in combination with trastuzumab/trastuzumab biosimilars.
|
| No information available. |
Summary of Clinical Use  |
| HLX22 has progressed to clinical evaluations in advanced solid tumours overexpressing EGFR2, and results from a phase 1 study as a monotherapy were reported in mid-2023 [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04908813 | Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer | Phase 2 Interventional | Shanghai Henlius Biotech | ||
| NCT03916094 | Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2 | Phase 1 Interventional | Shanghai Henlius Biotech | 2 | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License